119 related articles for article (PubMed ID: 2617702)
21. Hormonal therapy for oestrogen receptor-negative breast cancer is associated with higher disease-specific mortality.
Merglen A; Verkooijen HM; Fioretta G; Neyroud-Caspar I; Vinh-Hung V; Vlastos G; Chappuis PO; Castiglione M; Rapiti E; Bouchardy C
Ann Oncol; 2009 May; 20(5):857-61. PubMed ID: 19150951
[TBL] [Abstract][Full Text] [Related]
22. A 94 year old male stage IV breast cancer patient showing complete remission under tamoxifen treatment after operation.
Tateishi M; Toda T; Minamisono Y; Nagasaki S; Sugimachi K
J Surg Oncol; 1992 Sep; 51(1):71-3. PubMed ID: 1518297
[TBL] [Abstract][Full Text] [Related]
23. [The importance of steroid receptors for the prognosis and hormone treatment of breast cancer patients: a retrospective study in Southeastern Netherlands].
Voogd AC; Crommelin MA; Repelaer van Driel OJ; Tutein Nolthenius-Puylaert MC; Vreugdenhil G; Coebergh JW
Ned Tijdschr Geneeskd; 1998 Aug; 142(31):1772-8. PubMed ID: 9856143
[TBL] [Abstract][Full Text] [Related]
24. Lack of G protein-coupled estrogen receptor (GPER) in the plasma membrane is associated with excellent long-term prognosis in breast cancer.
Sjöström M; Hartman L; Grabau D; Fornander T; Malmström P; Nordenskjöld B; Sgroi DC; Skoog L; Stål O; Leeb-Lundberg LM; Fernö M
Breast Cancer Res Treat; 2014 May; 145(1):61-71. PubMed ID: 24715381
[TBL] [Abstract][Full Text] [Related]
25. Prognostic factors in elderly women with metastatic breast cancer treated with tamoxifen: an analysis of patients entered on four prospective clinical trials.
Dhodapkar MV; Ingle JN; Cha SS; Mailliard JA; Wieand HS
Cancer; 1996 Feb; 77(4):683-90. PubMed ID: 8616760
[TBL] [Abstract][Full Text] [Related]
26. Chemotherapy versus tamoxifen versus chemotherapy plus tamoxifen in node-positive, oestrogen-receptor positive breast cancer patients. An update at 7 years of the 1st GROCTA (Breast Cancer Adjuvant Chemo-Hormone Therapy Cooperative Group) trial.
Boccardo F; Rubagotti A; Amoroso D; Sismondi P; Genta F; Nenci I; Piffanelli A; Farris A; Castagnetta L; Traina A
Eur J Cancer; 1992; 28(2-3):673-80. PubMed ID: 1591091
[TBL] [Abstract][Full Text] [Related]
27. Impact of estrogen receptor expression and other clinicopathologic features on tamoxifen use in ductal carcinoma in situ.
Hird RB; Chang A; Cimmino V; Diehl K; Sabel M; Kleer C; Helvie M; Schott A; Young J; Hayes D; Newman L
Cancer; 2006 May; 106(10):2113-8. PubMed ID: 16596655
[TBL] [Abstract][Full Text] [Related]
28. Tamoxifen induces heparanase expression in estrogen receptor-positive breast cancer.
Cohen I; Maly B; Simon I; Meirovitz A; Pikarsky E; Zcharia E; Peretz T; Vlodavsky I; Elkin M
Clin Cancer Res; 2007 Jul; 13(14):4069-77. PubMed ID: 17634531
[TBL] [Abstract][Full Text] [Related]
29. The nature of tamoxifen action in the control of female breast cancer.
Kodama M; Kodama T
In Vivo; 2001; 15(4):319-25. PubMed ID: 11695224
[TBL] [Abstract][Full Text] [Related]
30. Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials.
Regan MM; Pagani O; Francis PA; Fleming GF; Walley BA; Kammler R; Dell'Orto P; Russo L; Szőke J; Doimi F; Villani L; Pizzolitto S; Öhlschlegel C; Sessa F; Peg Cámara V; Rodríguez Peralto JL; MacGrogan G; Colleoni M; Goldhirsch A; Price KN; Coates AS; Gelber RD; Viale G;
Breast Cancer Res Treat; 2015 Nov; 154(2):275-86. PubMed ID: 26493064
[TBL] [Abstract][Full Text] [Related]
31. Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX.
Aebi S; Sun Z; Braun D; Price KN; Castiglione-Gertsch M; Rabaglio M; Gelber RD; Crivellari D; Lindtner J; Snyder R; Karlsson P; Simoncini E; Gusterson BA; Viale G; Regan MM; Coates AS; Goldhirsch A
Ann Oncol; 2011 Sep; 22(9):1981-1987. PubMed ID: 21282282
[TBL] [Abstract][Full Text] [Related]
32. The impact of tamoxifen on breast recurrence, cosmesis, complications, and survival in estrogen receptor-positive early-stage breast cancer.
Fowble B; Fein DA; Hanlon AL; Eisenberg BL; Hoffman JP; Sigurdson ER; Daly MB; Goldstein LJ
Int J Radiat Oncol Biol Phys; 1996 Jul; 35(4):669-77. PubMed ID: 8690632
[TBL] [Abstract][Full Text] [Related]
33. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98.
Viale G; Regan MM; Maiorano E; Mastropasqua MG; Dell'Orto P; Rasmussen BB; Raffoul J; Neven P; Orosz Z; Braye S; Ohlschlegel C; Thürlimann B; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
J Clin Oncol; 2007 Sep; 25(25):3846-52. PubMed ID: 17679725
[TBL] [Abstract][Full Text] [Related]
34. Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: results of a large observational study.
Guerrieri-Gonzaga A; Botteri E; Lazzeroni M; Rotmensz N; Goldhirsch A; Varricchio C; Serrano D; Cazzaniga M; Bassi F; Luini A; Bagnardi V; Viale G; Mora S; Bollani G; Albertazzi E; Bonanni B; Decensi A
Ann Oncol; 2010 May; 21(5):949-54. PubMed ID: 19858087
[TBL] [Abstract][Full Text] [Related]
35. Gamma linolenic acid with tamoxifen as primary therapy in breast cancer.
Kenny FS; Pinder SE; Ellis IO; Gee JM; Nicholson RI; Bryce RP; Robertson JF
Int J Cancer; 2000 Mar; 85(5):643-8. PubMed ID: 10699943
[TBL] [Abstract][Full Text] [Related]
36. Tamoxifen therapy in premenopausal patients with metastatic breast cancer.
Pritchard KI; Thomson DB; Myers RE; Sutherland DJ; Mobbs BG; Meakin JW
Cancer Treat Rep; 1980; 64(6-7):787-96. PubMed ID: 7427962
[TBL] [Abstract][Full Text] [Related]
37. Relationship of PS2 with response to tamoxifen therapy in patients with recurrent breast cancer.
Foekens JA; Portengen H; Look MP; van Putten WL; Thirion B; Bontenbal M; Klijn JG
Br J Cancer; 1994 Dec; 70(6):1217-23. PubMed ID: 7981080
[TBL] [Abstract][Full Text] [Related]
38. Clinical experiences with tamoxifen for estrogen receptor blocking therapy in metastatic breast cancer.
Henningsen B
Prog Clin Biol Res; 1977; 12():479-82. PubMed ID: 918118
[No Abstract] [Full Text] [Related]
39. Hepatocellular carcinoma after long-term tamoxifen therapy.
Moffat DF; Oien KA; Dickson J; Habeshaw T; McLellan DR
Ann Oncol; 2000 Sep; 11(9):1195-6. PubMed ID: 11061618
[TBL] [Abstract][Full Text] [Related]
40. Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment.
Yu KD; Di GH; Wu J; Lu JS; Shen KW; Liu GY; Shen ZZ; Shao ZM
J Cancer Res Clin Oncol; 2008 Dec; 134(12):1347-54. PubMed ID: 18488249
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
